Sage Therapeutics (SAGE) News Today $5.27 -0.08 (-1.50%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Hold" from BrokeragesSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has earned a consensus rating of "Hold" from the twenty ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given aDecember 18 at 3:01 AM | marketbeat.comViridian Therapeutics: Promising THRIVE-2 Study Results Position Veligrotug as a Market Leader in Thyroid Eye Disease TreatmentDecember 17 at 1:25 PM | markets.businessinsider.comSage Therapeutics price target lowered to $6 from $10 at StifelDecember 17 at 1:25 PM | finance.yahoo.comSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $6.00 by Analysts at Stifel NicolausDecember 17 at 2:41 AM | americanbankingnews.comStifel Nicolaus Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $6.00Stifel Nicolaus decreased their target price on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a research note on Monday.December 16 at 8:37 AM | marketbeat.comMizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)December 12, 2024 | markets.businessinsider.comFmr LLC Sells 552,248 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Fmr LLC lowered its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 9.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 5,271,108 shares of the biopharmaceutical company's stock after selling 552,248 shares during the period.December 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $9.10 Million Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Jacobs Levy Equity Management Inc. decreased its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 11.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,260,017 shares of the bDecember 6, 2024 | marketbeat.comRTW Investments LP Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)RTW Investments LP increased its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 2.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,591,700 shares of the biopharDecember 5, 2024 | marketbeat.comSage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | businesswire.comMajor Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsightNovember 26, 2024 | finance.yahoo.comQ1 EPS Estimate for Sage Therapeutics Increased by AnalystSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued on Wednesday, November 20th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical comNovember 25, 2024 | marketbeat.comSage Therapeutics price target lowered to $4 from $7 at BofANovember 23, 2024 | markets.businessinsider.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from AnalystsSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been given an average rating of "Hold" by the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seventeen have issued a hoNovember 23, 2024 | marketbeat.comSage raised to sector perform by RBC in wake of drug failureNovember 22, 2024 | msn.comSage ends dalzanemdor development following Phase II trial failureNovember 22, 2024 | msn.comSAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber ChallengesNovember 22, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $9 from $10 at TD CowenNovember 22, 2024 | markets.businessinsider.comSage Therapeutics (NASDAQ:SAGE) Upgraded to "Sector Perform" at Royal Bank of CanadaRoyal Bank of Canada raised shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 target price on the stock in a report on Thursday.November 21, 2024 | marketbeat.comSage slips as Huntington’s Disease therapy fails in mid-stage trialNovember 20, 2024 | seekingalpha.comSAGE Therapeutics: Hold Rating Amid Strategic Shift Following Dalzanemdor DiscontinuationNovember 20, 2024 | markets.businessinsider.comSAGE Therapeutics: Hold Rating Amid Dalzanemdor’s Phase 2 Failure and Valuation AdjustmentsNovember 20, 2024 | markets.businessinsider.comSage Therapeutics to end development of key therapy after a third trial failureNovember 20, 2024 | msn.comSage Therapeutics (NASDAQ:SAGE) Earns Hold Rating from Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a report on Wednesday.November 20, 2024 | marketbeat.comSage Therapeutics scraps development of rare disease drug after it fails mid-stage studyNovember 20, 2024 | reuters.comCNS Drug Development: Same As It Ever WasNovember 19, 2024 | seekingalpha.comInvestment surges, hurdles and emerging innovations in neuroscienceNovember 11, 2024 | finance.yahoo.comEasterly Investment Partners LLC Has $326,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Easterly Investment Partners LLC reduced its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 67.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,102 shares of thNovember 9, 2024 | marketbeat.comJ.P. Morgan Sticks to Its Hold Rating for SAGE Therapeutics (SAGE)November 8, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $9 from $11 at Morgan StanleyNovember 5, 2024 | markets.businessinsider.comSAGE Therapeutics: Balancing Promising Sales Growth with Strategic Uncertainties – A Hold RatingNovember 5, 2024 | markets.businessinsider.comSage Therapeutics, Inc. (NASDAQ:SAGE) Position Reduced by Pinnacle Associates Ltd.Pinnacle Associates Ltd. trimmed its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 42.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 168,573 shares of the biopharmaceutical company's stocNovember 2, 2024 | marketbeat.comCambridge biotech's layoffs will cut dozens of Mass. employeesNovember 1, 2024 | bizjournals.comSAGE Therapeutics Announces Strategic Reorganization Amid Executive DeparturesNovember 1, 2024 | markets.businessinsider.comHC Wainwright Has Bearish Estimate for SAGE FY2024 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Wednesday, October 30th. HC Wainwright analyst D. Tsao now forecasts that theNovember 1, 2024 | marketbeat.comHold Rating on Sage Therapeutics Amid Promising Revenue but Uncertain Future ExpensesNovember 1, 2024 | markets.businessinsider.comHold Rating Maintained for SAGE Therapeutics Amid Positive Sales and Strategic ChallengesOctober 31, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Hold on SAGE Therapeutics (SAGE)October 31, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $26 from $52 at Piper SandlerOctober 31, 2024 | finance.yahoo.comWhat is HC Wainwright's Estimate for SAGE FY2028 Earnings?Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued on Wednesday, October 30th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will eOctober 31, 2024 | marketbeat.comSage Therapeutics Reports Q3 Growth and Strategic FocusOctober 31, 2024 | msn.comSage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...October 31, 2024 | finance.yahoo.comHold Rating on SAGE Therapeutics Amid Promising Developments and Strategic UncertaintiesOctober 31, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $14 from $17 at ScotiabankOctober 31, 2024 | markets.businessinsider.comScotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $14.00Scotiabank cut their price target on shares of Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating on the stock in a research report on Wednesday.October 30, 2024 | marketbeat.comPiper Sandler Reiterates "Overweight" Rating for Sage Therapeutics (NASDAQ:SAGE)Piper Sandler restated an "overweight" rating and set a $26.00 price target (down from $52.00) on shares of Sage Therapeutics in a research report on Wednesday.October 30, 2024 | marketbeat.comHold Rating on SAGE Therapeutics Amid Strong Zurzuvae Demand and Strategic ShiftsOctober 30, 2024 | markets.businessinsider.comSage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business UpdatesOctober 30, 2024 | stockhouse.comSage stock plunges 18% post-market following business update, earningsOctober 30, 2024 | msn.comHold Rating on SAGE Therapeutics Due to Stable Performance and High-Risk ProspectsOctober 30, 2024 | markets.businessinsider.com Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk threatens Liberal’s fake “energy crisis” (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.050.71▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼78▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ardelyx News Today Spyre Therapeutics News Today Calliditas Therapeutics AB (publ) News Today ARS Pharmaceuticals News Today ANI Pharmaceuticals News Today Syndax Pharmaceuticals News Today Rocket Pharmaceuticals News Today Bicycle Therapeutics News Today Avadel Pharmaceuticals News Today Collegium Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts